Immix Biopharma, Inc. (IMMX) stock forecast and price target
Price $7.84 · data as of November 13, 2026
12-month price target
Average target$23.80
Upside / downside+203.6%
Analysts8
ConsensusStrong buy
Low $17.40Average $23.80High $30.00
Gold marker: average target · white marker: today’s price ($7.84)
Analyst ratings
Strong buy 3Buy 4Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.73 | +17.6% | $0 |
| Next fiscal year ends December 31, 2027 | $-0.94 | −28.0% | $33M |
| Next quarter ends December 31, 2026 | $-0.18 | +35.7% | $0 |
| Quarter after ends March 31, 2027 | $-0.22 | −24.4% | $0 |
Consensus of the analysts covering Immix Biopharma, updated daily. In the last 30 days 2 estimates were raised and 1 lowered.
Frequently asked questions
What is the Immix Biopharma stock price target?
The average 12-month target from 8 analysts is $23.80, 203.6% above the current price of $7.84 Targets range from $17.40 to $30.00.
Is Immix Biopharma a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 4 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Immix Biopharma expected to earn?
Analysts expect EPS of $-0.73 for the fiscal year ending December 31, 2026 and $-0.94 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.